Mixed Medtronic Analyst Ratings
Major Financial Institutions Issue Mixed Ratings and Price Targets for Medtronic
Anonymous
Key Points
1
Medtronic updates were published on the same date, Sep 26, 2026, across all four firms (Wells Fargo, B Securities, Stifel, and Baird) referenced in the notes.
2
Across these Medtronic notes, the implied price-target band is 95 to 110, showing a modestly positive sentiment spread among the analysts.
3
The four updates illustrate a spectrum of ratings (Overweight, Buy, Hold, Neutral) among major firms, indicating a lack of consensus rather than a single market view.
4
In the same day’s coverage, Baird also published a note on CrowdStrike Holdings with Neutral and a target of 235, illustrating cross-sector analyst activity on the same date.
Wall Street analysts published mixed price targets for Medtronic on September 26, 2026, with forecasts ranging from $95 to $110 per share. Wells Fargo raised its target to $104 while keeping an Overweight rating, while B of A Securities lifted its target to $110 and maintained a Buy. Stifel Nicolaus bumped its target to $95 but kept a Hold rating, and Baird raised its target to $100 while holding Neutral. The spread reflects ongoing debate about the medical device maker's growth prospects.
The rating divergence—ranging from Buy to Neutral—shows analysts lack consensus on Medtronic's near-term risk and reward. Price targets climbed independently of ratings, suggesting analysts raised earnings forecasts and margin expectations without shifting their overall conviction levels.
A Wide Band of Bullish and Cautious Views
The four analyst notes reveal no single market consensus on Medtronic. Wells Fargo turned most bullish with a $104 target and Overweight stance. B of A Securities pushed highest at $110 with its Buy rating. Stifel took a more reserved tone, setting $95 while maintaining Hold. Baird split the difference at $100 with Neutral. This $15 spread—from $95 to $110—hints at real disagreement over the company's value.
Price Targets Rise While Ratings Stay Put
All four firms lifted their Medtronic targets on the same day, yet three of them kept their old ratings intact. Wells Fargo and B of A Securities already held Overweight and Buy, while Stifel and Baird stuck with Hold and Neutral despite raising prices. This gap shows targets move faster than ratings. Analysts revised earnings and margin forecasts upward without becoming more bullish on overall risk and reward.
Separate CrowdStrike Call Shows Cross-Sector Activity
On the same September 26 date, Baird also published research on CrowdStrike Holdings and maintained a Neutral rating while raising its price target to $235. The move reflects broader analyst activity across sectors—medical devices and cybersecurity both drew updates the same day. Baird's willingness to raise CrowdStrike's target without upgrading the rating mirrors its Medtronic approach, showing a pattern of target revisions outpacing conviction shifts.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
13
Reach
24
A
AnonymousAuthor
